DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller Sells 352 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller sold 352 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $70.33, for a total value of $24,756.16. Following the completion of the transaction, the director now directly owns 22,997 shares of the company’s stock, valued at approximately $1,617,379.01. The trade was a 1.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

DexCom Stock Up 3.8 %

Shares of DXCM opened at $73.38 on Thursday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $28.67 billion, a price-to-earnings ratio of 51.31, a PEG ratio of 2.30 and a beta of 1.28. The stock’s 50-day moving average price is $83.51 and its 200-day moving average price is $76.93.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Hedge Funds Weigh In On DexCom

A number of large investors have recently bought and sold shares of DXCM. Empowered Funds LLC raised its holdings in DexCom by 6.1% in the 3rd quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company’s stock worth $392,000 after purchasing an additional 335 shares during the period. Mutual of America Capital Management LLC raised its holdings in shares of DexCom by 3.8% during the third quarter. Mutual of America Capital Management LLC now owns 57,138 shares of the medical device company’s stock valued at $3,831,000 after acquiring an additional 2,084 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of DexCom by 44.2% during the third quarter. Thrivent Financial for Lutherans now owns 314,102 shares of the medical device company’s stock valued at $21,058,000 after acquiring an additional 96,274 shares during the last quarter. Swiss National Bank raised its holdings in shares of DexCom by 3.4% during the third quarter. Swiss National Bank now owns 1,180,400 shares of the medical device company’s stock valued at $79,134,000 after acquiring an additional 39,000 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in shares of DexCom by 305.4% during the third quarter. Fifth Third Wealth Advisors LLC now owns 29,646 shares of the medical device company’s stock valued at $1,987,000 after acquiring an additional 22,334 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DXCM shares. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.